AstraZeneca Core EPS Rises 17% To $2.79 As Cancer Drugs Absorb Farxiga Generic Hit

Oncology revenue climbed 17% to $7,765 million in the third quarter, and the drugmaker kept its 2026 outlook unchanged.

Share
AstraZeneca Core EPS Rises 17% To $2.79 As Cancer Drugs Absorb Farxiga Generic Hit

AstraZeneca, the drugmaker behind the cancer medicines Imfinzi, Tagrisso and Enhertu, said Friday that third-quarter revenue rose 7% to $16,209 million, with cancer growth outweighing the loss of exclusivity on Farxiga and Brilinta. Core earnings per share rose 17% to $2.79, and the company reconfirmed its 2026 guidance.

Cancer drugs carry the quarter

Revenue grew 7% both as reported and at constant exchange rates. Core EPS rose 17% as reported and 19% at constant rates, while reported EPS climbed 23% to $2.02, or 26% at constant rates.

Oncology product revenue rose 17% to $7,765 million. Imfinzi grew 24% to $1,990 million as reported, Tagrisso 12% to $2,087 million, and Enhertu 36% to $969 million.

The drag came from cardiovascular and metabolic drugs. Farxiga fell 25% to $1,605 million and Brilinta fell 48% to $75 million. Tezspire, the asthma drug, rose 50% to $429 million, and rare disease revenue reached $2,633 million.

Core operating profit rose 17% as reported to $5,855 million, or 20% at constant rates.

Guidance holds for 2026

At constant exchange rates, AstraZeneca still expects full-year total revenue to grow by a mid-to-high single-digit percentage and core EPS by a low double-digit percentage. It expects a core tax rate of 18-22%.

CEO Pascal Soriot said the company has had approvals for four new medicines and 12 positive late-stage trial readouts, with "a collective peak year revenue potential well in excess of ten billion dollars." The company counts 47 approvals in major regions since its fourth-quarter 2025 results.

Deals, restructuring and debt

In October AstraZeneca completed a $2 billion equity investment in Summit Therapeutics, giving it rights equal to about 12.0% of Summit's outstanding common stock. It also launched a restructuring programme, Reshaping for Sustainable Growth, expected to cost up to $2.0 billion in one-time charges and deliver $1.5 billion in annualised pre-tax run-rate benefits, with activities essentially complete by the end of 2029.

Net debt rose by $2,459 million over nine months to $25,833 million. The company intends to raise its 2026 dividend to $3.30 per share.

AstraZeneca plans to publish full-year and fourth-quarter 2026 results on 9 February 2027.

Sources

More on AstraZeneca

All AstraZeneca (AZN) coverage →